Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Repligen CorporationNASDAQ: RGEN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA dips below year-ago levels
Q2 FY2026 EBITDA of $45.92M fell 5.0% year over year, behind the +55.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 42.1% from the prior quarter. Over 3 fiscal years it compounded at -13.0% a year.
Context
- EBITDA amounted to 24.7% of revenue in FY2025, up 12.1 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 15 analysts of $255.33M (+39.9%) for the fiscal year ending Dec 2026, a slowdown from the +127.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $45.92M+42.1% QoQ
- Last fiscal yearDec 2025
- $182.51M+127.4% YoY
- LTMJun 2026
- $174.78M+55.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.0% | +21.9% | +26.9 pp |
| 1 year | +127.4% | +39.9% | -87.5 pp |
| 3-year CAGR | -13.0% | +27.7% | +40.7 pp |
| 5-year CAGR | +23.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 182.51M USD
- Year-over-year change
- +127.4%
- 4-year CAGR
- -2.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 182.51M | +127.4% |
| FY2024 | 2024-12-31 | 80.26M | -44.8% |
| FY2023 | 2023-12-31 | 145.32M | -47.6% |
| FY2022 | 2022-12-31 | 277.31M | +36.4% |
| FY2021 | 2021-12-31 | 203.27M | — |
EBITDA vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's LTM Jun 2026 EBITDA of $174.78M is the 6th highest of the 9 companies compared; the peer median is $421.73M.
- Its year-over-year change of +55.7% is the 2nd highest of 9, against a peer median of -1.2%.
- EBITDA amounts to 22.3% of revenue for RGEN, versus a peer median of 25.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.24B | -0.8% | -1.3% | 23.7% | |
| LTM Jul 2026 | $2.04B | +13.2% | -1.2% | 27.6% | |
| LTM Jun 2026 | $703.39M | -1.6% | -2.7% | 33.5% | |
| LTM Jun 2026 | $514.7M | -22.7% | — | 19.9% | |
| LTM Sep 2026 | $328.77M | +48.3% | -9.1% | 26.8% | |
| LTM Jun 2026 | $174.78M | +55.7% | -13.0% | 22.3% | |
| LTM Jun 2026 | $125.3M | -91.1% | -55.0% | 1.9% | |
| LTM Mar 2026 | -$7.46M | -184.6% | — | 7.5% | |
| LTM Jun 2026 | -$55.57M | +77.9% | — | 26.6% | |
| Peer median (excluding RGEN) | $421.73M | -1.2% | -2.7% | 25.2% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 670.53M | 801.54M | 632.36M | 634.44M | 738.26M |
| Cost of Revenue | 279.28M | 345.83M | 353.92M | 359.79M | 390.63M |
| Gross Profit | 391.25M | 455.71M | 278.44M | 274.65M | 347.62M |
| Gross Margin | 58.3% | 56.9% | 44.0% | 43.3% | 47.1% |
| Research & Development | 34.27M | 43.94M | 42.72M | 43.2M | 54.18M |
| Selling, General & Admin | 183.87M | 215.83M | 218.58M | 263.37M | 290.51M |
| Operating Expenses | 224.01M | 231.04M | 230.74M | 309.76M | 288.05M |
| Depreciation & Amortization | 38.45M | 57.01M | 86.11M | 86.56M | 96.96M |
| EBITDA | 203.27M | 277.31M | 145.32M | 80.26M | 182.51M |
| EBITDA Margin | 30.3% | 34.6% | 23.0% | 12.7% | 24.7% |
| Operating Income | 167.25M | 224.67M | 47.7M | (35.11M) | 59.58M |
| Operating Margin | 24.9% | 28.0% | 7.5% | -5.5% | 8.1% |
| Interest Income | 176K | 6.98M | 0 | 0 | 27.57M |
| Interest Expense | 12.71M | 2.98M | 10.03M | 22.57M | 23.17M |
| Other Income / Expenses | (13.71M) | (5.53M) | 9M | 8.08M | 2.81M |
| Income Before Tax | 153.54M | 219.14M | 56.71M | (27.04M) | 62.38M |
| Pre-Tax Margin | 22.9% | 27.3% | 9.0% | -4.3% | 8.5% |
| Income Tax Expense | 25.25M | 33.18M | 21.11M | (1.52M) | 13.49M |
| Net Income | 128.29M | 185.96M | 35.6M | (25.51M) | 48.89M |
| Net Margin | 19.1% | 23.2% | 5.6% | -4.0% | 6.6% |
| EPS (Basic) | 2.33 | 3.35 | 0.64 | (0.46) | 0.87 |
| EPS (Diluted) | 2.24 | 3.24 | 0.63 | (0.46) | 0.86 |
| Weighted Avg Shares | 55.02M | 55.46M | 55.72M | 55.94M | 56.23M |
| Weighted Avg Shares (Diluted) | 57.26M | 57.46M | 56.38M | 55.94M | 56.56M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.